AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO – Get Rating) was the target of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 816,800 shares, a decline of 14.8% from the December 15th total of 958,500 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.7 days. Approximately 2.7% of the company’s shares are short sold.
AVEO Pharmaceuticals Stock Performance
NASDAQ AVEO opened at $15.00 on Friday. The company has a quick ratio of 2.35, a current ratio of 2.37 and a debt-to-equity ratio of 0.94. AVEO Pharmaceuticals has a twelve month low of $3.06 and a twelve month high of $15.00. The firm has a market capitalization of $521.45 million, a PE ratio of -17.86 and a beta of 1.00. The stock’s 50 day moving average is $14.92 and its 200 day moving average is $11.25.
AVEO Pharmaceuticals (NASDAQ:AVEO – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.07. AVEO Pharmaceuticals had a negative return on equity of 81.66% and a negative net margin of 30.79%. The company had revenue of $30.45 million for the quarter, compared to analyst estimates of $29.95 million. Research analysts forecast that AVEO Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Institutional Investors Weigh In On AVEO Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in AVEO Pharmaceuticals in the third quarter worth $133,000. BNP Paribas Arbitrage SNC bought a new stake in AVEO Pharmaceuticals in the third quarter worth $49,000. Alliancebernstein L.P. bought a new stake in AVEO Pharmaceuticals in the third quarter worth $1,026,000. Two Sigma Advisers LP bought a new stake in AVEO Pharmaceuticals in the third quarter worth $132,000. Finally, Two Sigma Investments LP bought a new stake in AVEO Pharmaceuticals in the third quarter worth $387,000. 49.95% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E.
- Get a free copy of the StockNews.com research report on AVEO Pharmaceuticals (AVEO)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.